Keros Therapeutics, Inc.
NASDAQ:KROS · NASDAQ Global Market
+$0.13 today
Vol 0.40M · Avg 0.36M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
28.7%
avg -329.2%
ROIC
20.9%
avg -38.6%
ROA
25.7%
avg -29.7%
Analysis
ROE is currently the strongest return metric at 28.7% versus its period average of -329.2%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jasbir S. Seehra | President, Chief Executive Officer & Director | $1.11M | — | 70 | $440,708.00 | 1.38% |
Keith C. Regnante | Chief Financial Officer | $649,232.00 | — | 56 | $60,000.00 | 0.19% |
Esther Cho | Chief Legal Officer & Secretary | $634,192.00 | — | 37 | $80,000.00 | 0.25% |
Lorena Lerner | Chief Scientific Officer | — | — | 54 | $31,127.00 | 0.10% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$54,890.00
Sells
10
$16.37M
Net Sentiment
$16.32M
Net selling
Most Active
BIENAIME JEAN JACQUES
4 transactions
1–10 of 14
Analysis
Insiders reported 4 buys worth $54,890.00 and 10 sells worth $16.37M over the last 12 months. That adds up to net selling of $16.32M. BIENAIME JEAN JACQUES was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.42B
Absci Corporation
NASDAQ:ABSI
$1.14B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$995.63M
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$804.20M
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
$609.46M
CytomX Therapeutics, Inc.
NASDAQ:CTMX
$472.02M
REGENXBIO Inc.
NASDAQ:RGNX
$419.01M
Verastem, Inc.
NASDAQ:VSTM
$289.73M
Niagen Bioscience Inc
NASDAQ:NAGE
$277.56M
Who manages KROS?
Keros Therapeutics, Inc. (KROS) lists 4 active executives. The top listed executive is Jasbir S. Seehra, President, Chief Executive Officer & Director.
Are KROS insiders buying or selling?
Recent insider activity shows net buying of $33.38M.
Explore More
Continue the stock analysis
Jump to another research area for this company.